303 related articles for article (PubMed ID: 33462210)
1. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
[TBL] [Abstract][Full Text] [Related]
2. Methylation and PTEN activation in dental pulp mesenchymal stem cells promotes osteogenesis and reduces oncogenesis.
Shen WC; Lai YC; Li LH; Liao K; Lai HC; Kao SY; Wang J; Chuong CM; Hung SC
Nat Commun; 2019 May; 10(1):2226. PubMed ID: 31110221
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
[TBL] [Abstract][Full Text] [Related]
4. SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
Zhang J; Gao K; Xie H; Wang D; Zhang P; Wei T; Yan Y; Pan Y; Ye W; Chen H; Shi Q; Li Y; Zhao SM; Hou X; Weroha SJ; Wang Y; Zhang J; Karnes RJ; He HH; Wang L; Wang C; Huang H
Nat Commun; 2021 Sep; 12(1):5716. PubMed ID: 34588438
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.
Tsukamoto S; Løvendorf MB; Park J; Salem KZ; Reagan MR; Manier S; Zavidij O; Rahmat M; Huynh D; Takagi S; Kawano Y; Kokubun K; Thrue CA; Nagano K; Petri A; Roccaro AM; Capelletti M; Baron R; Kauppinen S; Ghobrial IM
Leukemia; 2018 Aug; 32(8):1739-1750. PubMed ID: 29925904
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
13. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.
Dotterweich J; Schlegelmilch K; Keller A; Geyer B; Schneider D; Zeck S; Tower RJ; Ebert R; Jakob F; Schütze N
Bone; 2016 Dec; 93():155-166. PubMed ID: 27519972
[TBL] [Abstract][Full Text] [Related]
14. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
[TBL] [Abstract][Full Text] [Related]
15. Current and potential epigenetic targets in multiple myeloma.
Pawlyn C; Kaiser MF; Davies FE; Morgan GJ
Epigenomics; 2014 Apr; 6(2):215-28. PubMed ID: 24811790
[TBL] [Abstract][Full Text] [Related]
16. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.
Li B; Shi M; Li J; Zhang H; Chen B; Chen L; Gao W; Giuliani N; Zhao RC
Stem Cells Dev; 2007 Dec; 16(6):921-30. PubMed ID: 17927494
[TBL] [Abstract][Full Text] [Related]
17. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
[TBL] [Abstract][Full Text] [Related]
18. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
Amodio N; Leotta M; Bellizzi D; Di Martino MT; D'Aquila P; Lionetti M; Fabiani F; Leone E; Gullà AM; Passarino G; Caraglia M; Negrini M; Neri A; Giordano A; Tagliaferri P; Tassone P
Oncotarget; 2012 Oct; 3(10):1246-58. PubMed ID: 23100393
[TBL] [Abstract][Full Text] [Related]
19. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.
Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L
Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861
[TBL] [Abstract][Full Text] [Related]
20. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
